BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has been assigned a $5.00 price target by stock analysts at HC Wainwright in a research note issued on Friday. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 70.94% from the company’s previous close.

A number of other research firms have also recently commented on BDSI. Cantor Fitzgerald reissued an “overweight” rating on shares of BioDelivery Sciences International in a research report on Sunday, August 20th. Zacks Investment Research cut shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. Janney Montgomery Scott increased their target price on shares of BioDelivery Sciences International from $3.00 to $4.00 and gave the company a “fair value” rating in a research report on Monday, July 24th. Roth Capital set a $5.00 target price on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Thursday. Finally, Piper Jaffray Companies set a $4.00 target price on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $4.29.

Shares of BioDelivery Sciences International (BDSI) opened at 2.925 on Friday. The stock has a market cap of $162.26 million, a PE ratio of 104.464 and a beta of 0.95. BioDelivery Sciences International has a 12-month low of $1.50 and a 12-month high of $3.60. The stock’s 50 day moving average is $2.95 and its 200-day moving average is $2.58.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.04). BioDelivery Sciences International had a net margin of 3.34% and a return on equity of 14.64%. The firm had revenue of $8.70 million for the quarter, compared to analysts’ expectations of $8.45 million. During the same period in the previous year, the company earned ($0.31) EPS. The company’s revenue was up 74.0% on a year-over-year basis. Equities analysts expect that BioDelivery Sciences International will post $0.12 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/13/hc-wainwright-analysts-give-biodelivery-sciences-international-inc-bdsi-a-5-00-price-target.html.

In other BioDelivery Sciences International news, insider Mark A. Sirgo sold 201,373 shares of the firm’s stock in a transaction on Thursday, September 21st. The shares were sold at an average price of $2.84, for a total value of $571,899.32. Following the completion of the transaction, the insider now owns 1,509,262 shares of the company’s stock, valued at $4,286,304.08. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Mark A. Sirgo sold 65,405 shares of the firm’s stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $2.75, for a total transaction of $179,863.75. Following the completion of the transaction, the chief executive officer now directly owns 1,509,262 shares of the company’s stock, valued at approximately $4,150,470.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 402,127 shares of company stock valued at $1,142,798. Corporate insiders own 9.00% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Cutter & CO Brokerage Inc. raised its holdings in shares of BioDelivery Sciences International by 2.4% in the second quarter. Cutter & CO Brokerage Inc. now owns 43,430 shares of the specialty pharmaceutical company’s stock worth $122,000 after buying an additional 1,000 shares during the last quarter. Northern Trust Corp raised its holdings in shares of BioDelivery Sciences International by 0.9% in the second quarter. Northern Trust Corp now owns 140,450 shares of the specialty pharmaceutical company’s stock worth $394,000 after buying an additional 1,203 shares during the last quarter. NEXT Financial Group Inc raised its holdings in shares of BioDelivery Sciences International by 9.3% in the second quarter. NEXT Financial Group Inc now owns 47,000 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 4,000 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of BioDelivery Sciences International by 19.9% in the second quarter. Janney Montgomery Scott LLC now owns 71,800 shares of the specialty pharmaceutical company’s stock worth $201,000 after buying an additional 11,900 shares during the last quarter. Finally, Advisor Group Inc. raised its holdings in shares of BioDelivery Sciences International by 42.1% in the second quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock worth $126,000 after buying an additional 13,341 shares during the last quarter. 41.43% of the stock is owned by institutional investors and hedge funds.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.